Urinary PGE-M

A promising cancer biomarker

Dingzhi Wang, Raymond N. DuBois

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cancer prevention, early diagnosis, and targeted therapies are the keys to success in better cancer control and treatment. A big challenge remains to identify biomarkers for predicting who may have higher cancer risk and are able to respond to certain chemopreventive agents as well as for assessing a patient's response during treatment. Although a large body of evidence indicates that chronic inflammation is a risk factor for cancer, it is unclear whether inflammatory biomarkers can be used to predict cancer risk, progression, and death. Considering the importance of the proinflammatory COX-2-derived prostaglandin E2 (PGE2) in inflammation and cancer, Morris and colleagues found that urinary PGE-M is positively associated with obesity, smoking, and lung metastases in patients with breast cancer (4). Along the same lines, Kim and colleagues showed a potential association between urinary PGE-M and breast cancer risk in postmenopausal women (beginning on page 511). In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression.

Original languageEnglish (US)
Pages (from-to)507-510
Number of pages4
JournalCancer Prevention Research
Volume6
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Tumor Biomarkers
Neoplasms
Biomarkers
Breast Neoplasms
Inflammation
Early Detection of Cancer
Dinoprostone
Disease Progression
Therapeutics
Obesity
Smoking
7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Urinary PGE-M : A promising cancer biomarker. / Wang, Dingzhi; DuBois, Raymond N.

In: Cancer Prevention Research, Vol. 6, No. 6, 06.2013, p. 507-510.

Research output: Contribution to journalArticle

Wang, Dingzhi ; DuBois, Raymond N. / Urinary PGE-M : A promising cancer biomarker. In: Cancer Prevention Research. 2013 ; Vol. 6, No. 6. pp. 507-510.
@article{53bc14c66dd146e089b8b9186a649fb4,
title = "Urinary PGE-M: A promising cancer biomarker",
abstract = "Cancer prevention, early diagnosis, and targeted therapies are the keys to success in better cancer control and treatment. A big challenge remains to identify biomarkers for predicting who may have higher cancer risk and are able to respond to certain chemopreventive agents as well as for assessing a patient's response during treatment. Although a large body of evidence indicates that chronic inflammation is a risk factor for cancer, it is unclear whether inflammatory biomarkers can be used to predict cancer risk, progression, and death. Considering the importance of the proinflammatory COX-2-derived prostaglandin E2 (PGE2) in inflammation and cancer, Morris and colleagues found that urinary PGE-M is positively associated with obesity, smoking, and lung metastases in patients with breast cancer (4). Along the same lines, Kim and colleagues showed a potential association between urinary PGE-M and breast cancer risk in postmenopausal women (beginning on page 511). In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression.",
author = "Dingzhi Wang and DuBois, {Raymond N.}",
year = "2013",
month = "6",
doi = "10.1158/1940-6207.CAPR-13-0153",
language = "English (US)",
volume = "6",
pages = "507--510",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Urinary PGE-M

T2 - A promising cancer biomarker

AU - Wang, Dingzhi

AU - DuBois, Raymond N.

PY - 2013/6

Y1 - 2013/6

N2 - Cancer prevention, early diagnosis, and targeted therapies are the keys to success in better cancer control and treatment. A big challenge remains to identify biomarkers for predicting who may have higher cancer risk and are able to respond to certain chemopreventive agents as well as for assessing a patient's response during treatment. Although a large body of evidence indicates that chronic inflammation is a risk factor for cancer, it is unclear whether inflammatory biomarkers can be used to predict cancer risk, progression, and death. Considering the importance of the proinflammatory COX-2-derived prostaglandin E2 (PGE2) in inflammation and cancer, Morris and colleagues found that urinary PGE-M is positively associated with obesity, smoking, and lung metastases in patients with breast cancer (4). Along the same lines, Kim and colleagues showed a potential association between urinary PGE-M and breast cancer risk in postmenopausal women (beginning on page 511). In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression.

AB - Cancer prevention, early diagnosis, and targeted therapies are the keys to success in better cancer control and treatment. A big challenge remains to identify biomarkers for predicting who may have higher cancer risk and are able to respond to certain chemopreventive agents as well as for assessing a patient's response during treatment. Although a large body of evidence indicates that chronic inflammation is a risk factor for cancer, it is unclear whether inflammatory biomarkers can be used to predict cancer risk, progression, and death. Considering the importance of the proinflammatory COX-2-derived prostaglandin E2 (PGE2) in inflammation and cancer, Morris and colleagues found that urinary PGE-M is positively associated with obesity, smoking, and lung metastases in patients with breast cancer (4). Along the same lines, Kim and colleagues showed a potential association between urinary PGE-M and breast cancer risk in postmenopausal women (beginning on page 511). In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84878857014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878857014&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-13-0153

DO - 10.1158/1940-6207.CAPR-13-0153

M3 - Article

VL - 6

SP - 507

EP - 510

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 6

ER -